

## Instructions for the medical use of the drug

### NEVAMED ophthalmic suspension 0.3%

**Trade name:** Nevamed.

**MNN:** Nepafenac.

**Dosage form:** Eye drops. Ophthalmic suspension 0.3%.

**Pharmacotherapeutic group:** NSAIDs for local use.

**Composition: 1 ml of the drug contains:**

**active substance:** nepafenac 3 mg.

**Pharmacological properties:**

**Pharmacodynamics:**

Nepafenac is a precursor to the active form of NSAIDs with anti-inflammatory and analgesic effects. When applied topically, nepafenac penetrates the cornea of the eye, where, with the help of hydrolases, it is converted into the active form - amfenac. Amfenac inhibits the action of COX. When applied topically, nepafenac reduces ocular tissue swelling and pain and does not have a significant effect on IOP.

**Indications for use:**

- prevention and treatment of postoperative pain and inflammation during cataract surgery;
- reducing the risk of developing postoperative macular edema during cataract surgery in patients with diabetes.

**Directions for use and dosage:** For topical use only. The bottle must be shaken before use.

- For the prevention and treatment of postoperative pain and inflammation after cataract removal, the drug is instilled 1 drop into the conjunctival sac of the eye 1 time per day, if necessary up to 3 times per day. Treatment begins 1 day before cataract surgery and continues for the first 2 weeks of the postoperative period (including the day of surgery). An additional drop of the drug must be instilled 30-120 minutes before surgery.
- To reduce the risk of developing postoperative macular edema after cataract removal in patients with diabetes, instill 1 drop into the conjunctival sac of the eye 1 time per day, starting from the first day before cataract removal, on the day of surgery, further dosage regimen and duration of treatment are prescribed by the attending physician. An additional drop of the drug must be instilled 30-120 minutes before surgery.

**Contraindications:**

- hypersensitivity to the components of the drug and other NSAIDs;
- bronchial asthma, urticaria, acute rhinitis caused by taking acetylsalicylic acid or other NSAIDs;
- children under 18 years of age.

**Drug interactions:**

Concomitant use of topical NSAIDs and topical corticosteroids may slow or delay the healing process.

There are no data on the simultaneous use of prostaglandin analogues and Nevamed. Given their mechanisms of action, simultaneous use is not recommended.

If necessary, it can be used in combination with other ophthalmic drugs for topical use. In this case, the interval between their use should be at least 5 minutes.

**Special instructions:**

Patients should avoid exposure to sunlight. Patients with signs of corneal damage should immediately discontinue use of the drug and carefully examine the condition of the cornea. Experience with topical NSAIDs suggests that patients with complications from ophthalmologic surgery, corneal denervation, corneal epithelial defects, diabetes mellitus, superficial ocular disease (dry eye syndrome), rheumatoid arthritis, or repeated surgeries performed within a short period of time, may have an increased risk of developing adverse reactions from the cornea, which may pose a risk of vision loss.

The use of topical NSAIDs in combination with eye surgery can cause severe bleeding in the tissues of the eye (including hyphema).

**Use during pregnancy and lactation:** Use during pregnancy and women of childbearing age who do not use contraceptives, as well as during lactation, is not recommended.

**Use in pediatrics:** Nevamed is contraindicated in children under 18 years of age, since its safety and effectiveness when used at this age have not been studied.

**Impact on the ability to drive vehicles and operate machinery:**

After using the drug, a temporary decrease in the clarity of visual perception is possible, and until it is restored, it is not recommended to drive a car or engage in activities that require increased attention and reaction.

**Release form:**

Eye drops in a polyethylene bottle of 5 ml.

**Storage conditions:** Store at a temperature not exceeding 25 °C.

After opening the bottle, use the drug within 28 days.

**Shelf life:** 2 years.

**Conditions for dispensing from pharmacies:** Dispensed with a prescription.

**Made for:**

**MAXX-PHARM LTD.**

**London, Great Britain**